Oct 29, 4:03 PM ET
Dexcom reported third-quarter 2026 revenue of $1.344 billion, representing an 11% increase year-over-year, alongside GAAP operating income of $327.2 million. The company raised its full-year 2026 revenue guidance midpoint to between $5.20 billion and $5.25 billion and announced a new $1.0 billion share repurchase program. For shareholders, these results reflect continued top-line growth, margin expansion, and capital return initiatives.
- Worldwide revenue grew 11% year-over-year to $1.344 billion for the third quarter ended September 30, 2026.
- GAAP operating income reached $327.2 million, or 24.3% of revenue, compared to $242.5 million in the third quarter of 2025.
- The Board of Directors authorized a share repurchase program of up to $1.0 billion of common stock expiring no later than December 31, 2027.
- Full-year 2026 revenue guidance was raised to a range of $5.20 billion to $5.25 billion.
Read the filing on SEC.gov ↗
Sep 14, 4:33 PM ET
DexCom named Jereme Sylvain, its executive vice president and chief financial officer, to also serve as chief operating officer, effective September 14, 2026, with oversight of global operations and quality teams. His new offer letter sets a base salary of $767,000 and a target bonus of 75% of base salary.
- Sylvain keeps his CFO role and adds the COO title, effective September 14, 2026
- Base salary of $767,000; annual target bonus equal to 75% of base salary
- Offer letter dated September 11, 2026; a copy will be filed with the 10-Q for the quarter ended September 30, 2026
- CEO Jake Leach said Sylvain will help the company scale more effectively
Read the filing on SEC.gov ↗
Sep 10, 4:16 PM ET
DexCom appointed Glenn S. Boehnlein as a director effective September 10, 2026, increasing the board to thirteen members. He joins the Audit Committee and the Operations & Innovation Committee, and the filing describes him as independent under Nasdaq listing standards.
- Boehnlein most recently served as Vice President and Chief Financial Officer of Stryker Corporation from 2016 to 2025.
- Initial equity grant of restricted stock units with a fair value of $500,000, vesting annually over three years.
- Annual director equity grant expected around the 2027 Annual Meeting with a fair value of $347,500.
- Term expires at the 2027 annual meeting of stockholders.
Read the filing on SEC.gov ↗
Jul 30, 4:03 PM ET
Dexcom reported second-quarter 2026 revenue of $1.308 billion, up 13% from a year earlier, and GAAP diluted earnings of $0.64 per share, up from $0.45. The company raised the midpoint of its fiscal 2026 revenue guidance to $5.18 billion to $5.25 billion and increased its margin guidance, which points to stronger results for shareholders than previously expected.
- Q2 2026 revenue was $1.308 billion, up from $1.157 billion, with U.S. revenue up 11% and international revenue up 19%.
- GAAP net income was $249.1 million, or $0.64 per diluted share, versus $179.8 million, or $0.45, a year earlier.
- Fiscal 2026 revenue guidance is $5.18 billion to $5.25 billion, representing about 11% to 13% growth.
- Cash, cash equivalents and marketable securities totaled $1.95 billion as of June 30, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.